A lysosome-targeted dextran-doxorubicin nanodrug overcomes doxorubicin-induced chemoresistance of myeloid leukemia

Abstract

The hypoxic microenvironment is presumed to be a sanctuary for myeloid leukemia cells that causes relapse following chemotherapy, but the underlying mechanism remains elusive. Using a zebrafish xenograft model, we observed that the hypoxic hematopoietic tissue preserved most of the chemoresistant leukemic cells following the doxorubicin (Dox) treatment. And hypoxia upregulated TFEB, a master regulator of lysosomal biogenesis, and increased lysosomes in leukemic cells. Specimens from relapsed myeloid leukemia patients also harbored excessive lysosomes, which trapped Dox and prevented drug nuclear influx leading to leukemia chemoresistance. Pharmaceutical inhibition of lysosomes enhanced Dox-induced cytotoxicity against leukemic cells under hypoxia circumstance. To overcome lysosome associated chemoresistance, we developed a pH-sensitive dextran-doxorubicin nanomedicine (Dex-Dox) that efficiently released Dox from lysosomes and increased drug nuclear influx. More importantly, Dex-Dox treatment significantly improved the chemotherapy outcome in the zebrafish xenografts transplanted with cultured leukemic cells or relapsed patient specimens. Overall, we developed a novel lysosome targeting nanomedicine that is promising to overcome the myeloid leukemia chemoresistance.

Supplementary Information

The online version contains supplementary material available at 10.1186/s13045-021-01199-8.

To the Editor

The mechanism(s) of how hypoxia regulates chemoresistance remains unclear, and the potential targeting therapeutic strategy is poorly developed [1, 2]. The zebrafish is an elegant model to investigate the efficacy of anti-leukemic drugs and the interaction between tumor and microenvironment in vivo [3–5]. Here, using the zebrafish xenograft model, we identified the hypoxic caudal hematopoietic tissue (CHT) were enriched with lysosome-abundant chemoresistant leukemic cells and further developed a lysosome targeting nanomedicine to enhance the chemotherapy efficacy.

The two days post-fertilization (2dpf) zebrafish embryos are immunodeficient due to the absence of adaptive immune system [4] and were used for xenografting myeloid leukemia cells, including Kasumi-1, K562 and OA3, to investigate the chemoresistance mechanism. The accumulated leukemic cells in CHT increased from 3-h post-injection (hpi) to 16 hpi, but the total leukemic cell number were comparable (Fig. 1A–C, Additional file 1: Fig. S1A–F). Moreover, the CHT-localized leukemic cells were mainly distributed in the caudal vein plexus of CHT (Fig. 1H). To explore the chemosensitivity of leukemic cells in CHT, we treated K562- (Fig. 1D–G) and Kasumi-1-(Additional file 1: Fig. S1G–J) xenografted zebrafish with Dox. The fluorescence intensity, cell number and the expression of human ribosome gene L32 did not significantly reduce upon Dox treatment. The leukemia cells resided in CHT were negative with the apoptosis marker TUNEL, confirming that the cells were chemoresistant (Additional file 1: Fig. S1K, L).

Fig. 1.

Hypoxic CHT harbored chemoresistant leukemic cells with increased lysosomes that sequestered Dox to prevent its nuclear entry and cytotoxicity. A–C K562 cells were microinjected into 2dpf embryos. The cell number and fluorescent intensity of leukemic cells localized in CHT at different time points post-injection were counted. D–G K562-xenografted zebrafish were treated with Dox from one-day-post injection (1 dpi) to 3 dpi, and the leukemic cells in CHT were quantified with the fluorescent intensity (E), the cell number (F) and the mRNA expression of human ribosome gene L32 (G). H Dox-resistant Kasumi-1 cells were mainly localized in the CVP vessels visualized by flk:GFP fish. CVP-caudal vein plexus, CA-caudal aorta, ISV-intersegmental vessel. I The 2dpf zebrafish embryos were stained with the PIM antibody to detect hypoxia tissue. The CHT was labeled with yellow rectangles. J, K The Kasumi-1-xenografted zebrafish were stained with LysoTracker and quantified for lysosome enrichment in CHT and non-CHT in vivo. The entire CHT in the left panel was labeled with yellow rectangles, and the region in blue rectangles were magnified in the right panels to show details. L The subcellular localization of Dox in K562 cells was visualized by its autonomous red fluorescence in Dox, Dox + Baf or Dox + CQ. M The chemoresistant K562 cells that localized in CHT were more sensitive to Dox + CQ while CQ alone has no toxicity. Bar plots are shown as average ± SEM. The statistical significance between groups was determined using Student’s t-test or ANOVA analysis. *Indicates p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001

We then tested the 2dpf zebrafish embryos for hypoxia markers, and found the hypoxia indicator pimonidazole (PIM) and the hypoxia-associated genes hif1al were highly enriched in CHT (Fig. 1I and Additional file 2: Fig. S2A). Besides the lysosome-related genes TFEB, LAMP1 and LC3B also increased in K562 under hypoxia (Additional file 2: Fig. S2B). TFEB is a master regulator of lysosome biogenesis [6, 7], we then assumed that hypoxia might increase TFEB expression to activate lysosome biogenesis. Indeed, we found the lysosome-high cells and expressions of lysosome genes such as V-ATPase, LAMP1 and LAMP2 were highly enriched in hypoxic K562 and Kasumi-1 cells (Additional file 2: Fig. S2C–H). Furthermore, more CHT-localized leukemic cells were stained positive with LysoTracker compared with cells in other tissues of leukemia-zebrafish xenografts (Fig. 1J, K), indicating the hypoxic CHT preserved leukemic cells with enriched lysosomes.

We next explored the role of lysosome in regulating leukemia chemoresistance. Lysosome inhibitor bafilomycin (Baf) or chloroquine (CQ) efficiently decreased the ratio of LysoTracker- or LysoSensor-high K562 cells (Additional file 3: Fig. S3A–D). We examined the intracellular location of Dox using its autonomous red fluorescence. Dox was mainly located in lysosomes but transported into the nucleus when treated with Baf or CQ (Fig. 1L). Baf or CQ also enhanced the Dox-induced cytotoxicity against chemoresistant cells in hypoxia-cultured cells (Additional file 3: Fig. S3E) and in xenografted zebrafish (Fig. 1M, Additional file 3: Fig. S3F).

Although our results showed that lysosome inhibition promotes the Dox nuclear entry and cytotoxicity against chemoresistant leukemic cells, CQ failed to improve the leukemia treatment outcome clinically due to the toxic effect and low delivery efficiency [6–10]. Therefore, we developed the lysosome targeting Dex-Dox nanodrug in which Dox was covalently conjugated with polymerized dextran  (Dex) to evaluate the anti-leukemia effect. The drug release experiment showed that the acid-responsive-bond containing Dex_5k/150k-Dox were more efficient in releasing Dox at low pH than their negative control Dex_5k/150k-b-Dox (Additional file 4: Fig. S4G). The results of in vitro cell viability (Additional file 5: Fig. S5A, B), apoptosis (Additional file 5: Fig. S5C, D) and ROS levels (Additional file 5: Fig. S5E, F) showed that Dex_5k/150k-Dox had comparable cytotoxicity with Dox by eliminating normoxia-cultured Kasumi-1 or K562 cells. However, Dex_5k/150k-Dox significantly decreased cell viability than Dox in hypoxic K562 (Fig. 2A) and Kasumi-1 (Additional file 5: Fig. S5G). In leukemia-xenografted-zebrafish, Dex_5k/150k-Dox but not Dox remarkably eliminated chemoresistant K562 and Kasumi-1 cells in CHT (Fig. 2B and Additional file 5: Fig. S5H). Increasing lysosome pH with CQ attenuated the amplified cytotoxicity of Dex_5k-Dox (Additional file 5: Fig. S5I), indicating Dex-Dox depends on lysosome for exerting cytotoxicity.

Fig. 2.

The pH-sensitive Dex-Dox nanomedicine promoted the nuclear entry and cytotoxicity of Dox in hypoxic leukemic cells to overcome chemoresistance. A The hypoxia-cultured K562 cells have higher viability post Dox treatment, but the viability was significantly reduced in Dex_5k/150k-Dox. B The K562-xenografted-zebrafish embryos were treated with Dox or Dex_5k/150k-Dox, and leukemic cells in CHT were counted at two days post-treatment. The results showed that Dex_5k/150k-Dox had much higher toxicity against chemoresistant leukemic cells. C The subcellular localization of Dox was analyzed by its autonomous red fluorescence in Dox, Dex-Dox or Dex-b-Dox treated K562 cells. D, E The bone marrow specimen from the same patient (#1) at primary or relapsed stage were collected for staining with LysoTracker (D) or cell counting after treatment with Dox or Dex_5k/150k-Dox (E). F, G The bone marrow specimen from the relapsed patient #2 was collected and incubated in hypoxia to measure the ratio of LysoTracker-high cells (F) and count the cell number after treatment with Dox or Dex_5k/150k-Dox (G). H The zebrafish embryos were xenografted with the relapsed leukemic cells from patient #2 and treated with Dox or Dex_5k/150k-Dox. The fluorescent intensity of leukemic cells in CHT was quantified at two days post-treatment. Bar plots are shown as average ± SEM. The statistical significance between groups was determined using Student’s t-test or ANOVA analysis. * Indicates p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001

Mechanistically Dex-Dox induced apoptosis in chemoresistant leukemia cells as we found more TUNEL + K562 cells in Dex_5k-Dox treated CHT (Additional file 6: Fig. S6A, B). Futhermore, Dex_5k/150k-Dox released Dox from lysosomes to enter the nuclei (Fig. 2C), but had no effect on lysosome pH as compared to Dox (Additional file 6: Fig. S6C–H), suggesting Dex_5k/150k-Dox might exhibit anti-leukemic effect through facilitating Dox nuclear influx. In addition, Dox released from Dex-Dox nanomedicine was highly accumulated in zebrafish and transported into the CHT localized leukemic cells more efficiently than Dox alone (Additional file 7: Fig. S7A–D).

We further explored the therapeutic effect of Dex-Dox with myeloid leukemia patient samples. The leukemic cells from the relapsed patient had increased ratio of LysoTracker-high cells than the primary patient cells (Fig. 2D), and Dex_5k-Dox efficiently eliminated the relapsed cells than Dox (Fig. 2E). Similarly, the hypoxia-incubated leukemic cells had increased ratio of LysoTracker-high cells, and more resistant to Dox, but they were susceptible to Dex_150k-Dox treatment (Fig. 2F, G). We also found that Dex_5k/150k-Dox efficiently eliminated these relapsed patient cells in xenografted zebrafish (Fig. 2H, Additional file 7: Fig. S7E, F).

Overall, our data reveal that the hypoxia-lysosome axis controls the myeloid leukemia chemoresistance, and the newly developed lysosome targeting nanomedicine is a promising strategy to eliminate chemoresistant leukemic cells (Additional file 8: Fig. S8).

Abbreviations

Dox

Doxorubicin

Dex-Dox

Dextran-doxorubicin

CHT

Caudal hematopoietic tissue

2dpf

Two days post-fertilization

PIM

Pimonidazole

Baf

Bafilomycin

CQ

Chloroquine

Authors' contributions

YZ, DL designed and performed most of the biological experiments and analyzed the data. XF, YL, contributed to zebrafish experiments and analysis. XZ, ZF contributed to nanomedicine synthesis and characterization. WZ, YC contributed to the discussion. LJ, JW, MZ supervised the project and wrote the paper. All authors read and approved the final manuscript.

Funding

We would like to acknowledge the Key Research and Development Program of Guangdong Province (2019B020234002), International Cooperation and Exchange of the National Natural Science Foundation of China (51820105004), NSFC (31871467, 51973243, 81800164, 81870127), Shenzhen Basic Research Project (JCYJ20190807155801657), Guangdong Basic and Applied Basic Research Foundation (2018A030313497, 2019A1515110903, 2021B1515020012), Sanming Project of Medicine in Shenzhen (SZSM201911004).

Availability of data and materials

All data generated during this study are included in this published article.

Declarations

Ethics approval and consent to participate

The use of the patient samples was approved by the ethics committee of the 7th Affiliated Hospital at Sun Yat-Sen University following international guidelines and the ethical standards outlined in the Declaration of HELSINKI.

Consent for publication

All patients are consent for publication.

Competing interests

The authors declare that they have no competing interests.